Parveen Fathima1, Christopher C Blyth1,2,3,4, Deborah Lehmann1, Faye J Lim1, Tasnim Abdalla1, Nicholas de Klerk1, Hannah C Moore1. 1. Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute. 2. School of Medicine, University of Western Australia. 3. Department of Infectious Diseases, Princess Margaret Hospital for Children. 4. Department of Microbiology, PathWest Laboratory Medicine WA, QEII Medical Centre, Perth, Western Australia.
Abstract
Background: Pneumococcal conjugate vaccine (PCV) was included in Australia's National Immunisation Program for all children from 2005. We assessed the impact of PCV on all-cause and pathogen-specific pneumonia hospitalizations in Western Australian (WA) children aged ≤16 years. Methods: All hospitalizations with pneumonia-related International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification diagnosis codes occurring in WA-born children (1996-2012) were linked to pathology records. Age-specific incidence rate ratios and temporal trends for all-cause and pathogen-specific pneumonia hospitalizations were calculated before and after PCV introduction. Results: Among 469589 births, there were 15175 pneumonia-related hospitalizations. Hospitalization rates were 6.7 (95% confidence interval, 6.4-6.9) times higher in Aboriginal than in non-Aboriginal children. Following PCV introduction, all-cause pneumonia hospitalizations showed significant declines across all age groups. A pathogen was identified in 2785 of 6693 (41.6%) pneumonia hospitalizations that linked to a pathology record. Respiratory syncytial virus (RSV) was most frequently identified, with RSV-associated pneumonia hospitalization rates of 89.6/100000 child-years in Aboriginal and 26.6/100000 child-years in non-Aboriginal children. The most common bacterial pathogen was Streptococcus pneumoniae in Aboriginal children (32.9/100000 child-years) and Mycoplasma pneumoniae in non-Aboriginal children (8.4/100000 child-years). Viral pneumonia rates declined in all children following PCV introduction, with the greatest declines seen in non-Aboriginal children; declines in bacterial pneumonia were observed in non-Aboriginal children. Conclusions: Based on our ecological analyses, PCV seems to have had an impact on hospitalizations for pneumonia, suggesting that the pneumococcus is likely to play a role in both bacterial and viral pneumonia. Respiratory viruses remain an important pathogen in childhood pneumonia. Vaccines targeting respiratory viruses are needed to combat the residual burden of childhood pneumonia.
Background: Pneumococcal conjugate vaccine (PCV) was included in Australia's National Immunisation Program for all children from 2005. We assessed the impact of PCV on all-cause and pathogen-specific pneumonia hospitalizations in Western Australian (WA) children aged ≤16 years. Methods: All hospitalizations with pneumonia-related International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification diagnosis codes occurring in WA-born children (1996-2012) were linked to pathology records. Age-specific incidence rate ratios and temporal trends for all-cause and pathogen-specific pneumonia hospitalizations were calculated before and after PCV introduction. Results: Among 469589 births, there were 15175 pneumonia-related hospitalizations. Hospitalization rates were 6.7 (95% confidence interval, 6.4-6.9) times higher in Aboriginal than in non-Aboriginal children. Following PCV introduction, all-cause pneumonia hospitalizations showed significant declines across all age groups. A pathogen was identified in 2785 of 6693 (41.6%) pneumonia hospitalizations that linked to a pathology record. Respiratory syncytial virus (RSV) was most frequently identified, with RSV-associated pneumonia hospitalization rates of 89.6/100000 child-years in Aboriginal and 26.6/100000 child-years in non-Aboriginal children. The most common bacterial pathogen was Streptococcus pneumoniae in Aboriginal children (32.9/100000 child-years) and Mycoplasma pneumoniae in non-Aboriginal children (8.4/100000 child-years). Viral pneumonia rates declined in all children following PCV introduction, with the greatest declines seen in non-Aboriginal children; declines in bacterial pneumonia were observed in non-Aboriginal children. Conclusions: Based on our ecological analyses, PCV seems to have had an impact on hospitalizations for pneumonia, suggesting that the pneumococcus is likely to play a role in both bacterial and viral pneumonia. Respiratory viruses remain an important pathogen in childhood pneumonia. Vaccines targeting respiratory viruses are needed to combat the residual burden of childhood pneumonia.
Authors: Claire von Mollendorf; Mukhchuluun Ulziibayar; Bradford D Gessner; Lien Anh Ha Do; Cattram D Nguyen; Rohini Beavon; Bujinlkham Suuri; Dashtseren Luvsantseren; Dorj Narangerel; Adam Jenney; Eileen M Dunne; Catherine Satzke; Badarchiin Darmaa; Tuya Mungun; E Kim Mulholland Journal: BMC Public Health Date: 2021-09-23 Impact factor: 3.295
Authors: F Martinón-Torres; M Carmo; L Platero; G Drago; J L López-Belmonte; M Bangert; J Díez-Domingo; M Garcés-Sánchez Journal: BMC Infect Dis Date: 2022-09-29 Impact factor: 3.667
Authors: Mejbah Uddin Bhuiyan; Thomas L Snelling; Rachel West; Jurissa Lang; Tasmina Rahman; Meredith L Borland; Ruth Thornton; Lea-Ann Kirkham; Chisha Sikazwe; Andrew C Martin; Peter C Richmond; David W Smith; Adam Jaffe; Christopher C Blyth Journal: BMJ Open Date: 2018-03-16 Impact factor: 2.692
Authors: Mejbah Uddin Bhuiyan; Thomas L Snelling; Rachel West; Jurissa Lang; Tasmina Rahman; Caitlyn Granland; Camilla de Gier; Meredith L Borland; Ruth B Thornton; Lea-Ann S Kirkham; Chisha Sikazwe; Andrew C Martin; Peter C Richmond; David W Smith; Adam Jaffe; Christopher C Blyth Journal: Thorax Date: 2018-10-18 Impact factor: 9.139
Authors: Sam Manna; Julie McAuley; Jonathan Jacobson; Cattram D Nguyen; Md Ashik Ullah; Ismail Sebina; Victoria Williamson; E Kim Mulholland; Odilia Wijburg; Simon Phipps; Catherine Satzke Journal: mSphere Date: 2022-01-19 Impact factor: 4.389